Clinical Trials
12 trialsNCT04827563 2026-03-04
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
Terminated
NCT06787807 2025-01-22
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
Phase NA Not yet recruiting
NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
NCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT02589860 2022-01-10
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
Withdrawn
NCT01653106 2017-06-27
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT01066624 2015-07-23
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
The University of Texas Health Science Center at San Antonio
Phase NA Completed
NCT00482846 2014-04-15
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT01402687 2013-07-16
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Dana-Farber Cancer Institute
Completed
NCT00602147 2013-03-14
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Vanderbilt-Ingram Cancer Center
Terminated